Heidelberg Pharma Ag · XETR:HPHA
Heidelberg Pharma — Corporate Update (September 2025)
10 slides from Heidelberg Pharma's corporate update, Sep 25, 2025
Slide 1: Strategic and Operational Focusing
STRATEGIC AND OPERATIONAL FOCUSING Professor Andreas Pahl, CEO • 25 September 2025
Slide 2: Safe Harbor: Forward Looking Statements
SAFE HARBOR FORWARD LOOKING STATEMENTS This communication contains certain forward-looking statements, competition from other biopharmaceutical, chemical and relating to the Company’s business, which can be identified by the pharmaceutical companies, environmental, health and safety matters, use of
Slide 3: Current Situation
CURRENT SITUATION • Heidelberg Pharma monetized the potential royalty streams from TLX250-CDx (out-licensed to Telix Pharmaceuticals) - and built its financing strategy around this • USD 70 m milestone payment due upon FDA approval of TLX250-CDx and monies planned to be used to finance the ADC pipel
Slide 4: Agreement with HealthCare Royalty
AGREEMENT WITH HEALTHCARE ROYALTY Partial monetization of royalty stream for TLX250-CDx - an imaging agent for kidney cancer out-licensed to Telix Key terms of the agreement between Heidelberg Pharma and HealthCare Royalty: • USD 45 m upfront payments already received, not refundable • Maximum of US
Slide 5: TLX250-CDx: Excellent Potential for Detecting Renal Cancer
TLX250-CDx: EXCELLENT POTENTIAL FOR DETECTING RENAL CANCER Complete Response Letter received from FDA on 27 August 2025 • CRL does not relate to clinical study results or the safety/efficacy of the product, but Imaging of kidney cancer to better is focused on technical and regulatory aspects of manu
Slide 6: Strategic and Operational Focusing: Cost-Saving Measures
STRATEGIC AND OPERATIONAL FOCUSING HEIDELBERG PHARMA COST-SAVING MEASURES • Focus on lead program: Clinical Phase I/IIa trial with HDP-101 in Multiple Myeloma will continue as planned • Recently initiated Phase I trial with ADC candidate HDP-102 in Non-Hodgkin Lymphoma will be temporarily put on hol
Slide 7: HDP-101 Preliminary Efficacy Data
HDP-101 PRELIMINARY EFFICACY DATA OBJECTIVE RESPONSE RATES (ORR) 60% PRELIMINARY EFFICACY 50% • Multiple responses were seen (from 90 µg/kg) across 50% different dosing arms • In Cohort 6 (90 μg/kg), 2 of 10 patients showed PR 40% 36% 16.7% (1 patient is still ongoing with PR after 18 treatment cycl
Slide 8: HDP-102 Started Enrollment of Patients in Spring 2025
HDP-102 STARTED ENROLLMENT OF PATIENTS IN SPRING 2025 Multicenter, multinational open-label Phase Ia/Ib trial for relapsed/refractory B-cell malignancies General information • Broad potential application in B-cell malignancies • Cohort 1 is completed (40 µg/kg) • 3 patients enrolled: 1 DLBCL, 1 MZL,
Slide 9: ADC Pipeline in Liquid & Solid Tumor Indications
ADC PIPELINE IN LIQUID & SOLID TUMOR INDICATIONS HDP-101 HDP-102 HDP-103 HDP-104 BCMA-ATAC CD37-ATAC PSMA-ATAC GCC-ATAC for r/r Multiple Myeloma for Non-Hodgkin Lymphoma for mCR Prostate Cancer for colorectal cancer • Phase I/IIa study dose • CTA approval Q4 2024 • First-in-human enabling • IND-enab
Slide 10: Thank You for Your Attention
THANK YOU FOR YOUR Heidelberg Pharma AG Ladenburg, Germany Tel.: +49 6203 10090 ATTENTION investors@hdpharma.com investors@hdpharma.com www.heidelberg-pharma.com www.heidelberg-pharma.com
Heidelberg Pharma — Corporate Update (September 2025) on 6ix